final program for the 2015 cadth symposium

2015 CADTH SymposiumApril 12 to 14 | TCU Place | Saskatoon, SK

What Does theEvidenceSay?HTA to Support Policy and Practice

THANK YOU TO OUR SPONSORS

We would also like to acknowledge the support of our funders. CADTH’s activities, programs, and services, including the CADTH Symposium, are made possible through financial

contributions from Health Canada and the governments of:

We gratefully acknowledge the contribution of our sponsors to the success of the 2015 CADTH Symposium.

This event could not continue to grow and improve without you!

GOLD SPONSOR

SILVER SPONSOR

AlbertaBritish ColumbiaPrince Edward IslandManitobaNew BrunswickNova Scotia

NunavutOntarioSaskatchewanNewfoundland and LabradorNorthwest TerritoriesYukon

BRONZE SPONSORS

2015 CADTH Symposium

Welcome to the 2015 CADTH Symposium, the 11th annual pan-Canadian forum for producers and users of evidence-based information on drugs, medical devices, diagnostics, and procedures.

We’re very pleased to be holding the CADTH Symposium in Saskatoon, the Paris of the Prairies. Not only is Saskatoon a charming and vibrant city, but it’s also the largest city in Saskatchewan — the province where Canada’s publicly funded health system was born. Saskatchewan introduced the first provincial hospital insurance program in Canada in 1947 and the first free universal medical coverage in 1962. And so it seems appropriate that we’re gathering in Saskatchewan to discuss topics of great relevance to the continued quality and sustainability of the Canadian health care system.

This year’s theme — What Does the Evidence Say? HTA to Support Policy and Practice — reminds us to consider the evidence when making decisions about the uptake and use of health technologies. In the three plenary sessions, we’ll hear a wide range of perspectives from Canadian and international experts on what evidence they value, how they use it (or why they don’t), and what else they consider … we’ll also hear what the technologies of tomorrow will offer.

In addition, the CADTH Symposium offers 13 workshops, 20 panel sessions, 43 oral presentations, 4 breakfast sessions, and more than 60 scientific posters on a wide variety of topics including patient engagement, pharmaceutical and medical device policy issues, and applying evidence in a clinical setting.

There are also a number of informal networking opportunities at the CADTH Symposium, including the Welcome Reception and Scientific Poster Exhibition on Sunday evening, the 1910 Boomtown Dinner on Monday night, and the Awards Luncheon on Tuesday.

I hope that you find the discussions and networking productive and rewarding.

Dr. Brian O’Rourke President and CEO, CADTH

PROGRAM AT A GLANCE

1 | Page

SUNDAY, APRIL 12, 2015

Time Event Speakers Location 0800 – 1900 Registration Desk Open

0800 – 0900 Morning Workshop Registration Main Level Lobby

0900 – 1200 Workshop Full-Day 1 Introduction to Economic Modelling: Concepts and Practical Applications

Karen Lee Prof. Doug Coyle

Gallery D

0900 – 1200 Workshop AM-1 Finding the Evidence: Practical Tools for Literature Searching

Hayley Fitzsimmons Caitlyn Ford

Blair Nelson

Workshop AM-2 What the Evidence Says…May Depend on How It is Discussed

Dr. Durhane Wong-Rieger Dr. Andreas Laupacis Wayne Critchley Frank Gavin

Gallery B

Workshop AM-3 Critical Appraisal 101: Evidence Appraisal for the Non-Researcher

Dr. Sarah Jennings Brendalynn Ens Dr. Gabrielle Zimmermann Chris Kamel

Gallery A

Workshop AM-4 Issues in the Analysis of Health Care Cost Data

Dr. Nicholas Mitsakakis Dr. Petros Pechlivanoglou

Gallery C

Workshop AM-5 Complex Interventions for Comparative Effectiveness and Health Technology Assessment

Dr. Valeria Rac Dr. Lusine Abrahamyan Dr. Murray Krahn

Gallery Suite 1

Workshop AM-6 How Can Policy-Makers and Practitioners Apply the Results of Network Meta-Analysis to Real-World Decisions?

Shannon Sullivan Dr. Andrea Tricco Dr. Brian Hutton

Regal B

1200 – 1300 Afternoon Workshop Registration

Abstracts are available on the USB stick in the delegate kit, online at

www.cadth.ca/symposium2015, and through the CADTH Symposium App.

PROGRAM AT A GLANCE

2 | Page

SUNDAY, APRIL 12, 2014 (cont’d) Time Event Speakers Location 1300 – 1600 Workshop PM-1

Integrating Network Meta-Analysis in Economic Evaluations

Dr. Petros Pechlivanoglou

Dr. Areti-Angeliki Veroniki

Dr. Nicholas Mitsakakis Dr. Ba’ Pham

Gallery B

Workshop PM-2 Non-Inferiority Complex: Gaining Confidence in the Appraisal of Non-Inferiority Trials

Dr. Shawn Bugden Lynette Kosar

Blair Nelson

Workshop PM-3 Critical Appraisal 201: Evidence Appraisal for Non-Researchers

Dr. Sarah Jennings Brendalynn Ens Dr. Gabrielle

Zimmermann Chris Kamel

Gallery A

Workshop PM-4 Going Social: Social Media Literacy for the #HTA Crowd

Michelle Clark Caitlyn Ford Dr. Janice Mann

Gallery C

Workshop PM-5 Moving Evidence Into Daily Practice: How Saskatchewan is Using “Industrial Strength” Process Improvement (a.k.a. “LEAN”) to Improve Patient Care Across the Province

Dr. Susan Shaw Debra-Jane Wright Gary Teare Patrick Falastein Petrina McGrath

Gallery Suite 1

Workshop PM-6 Critical Appraisal of Clinical Trials Employing Adaptive Designs

Dr. Larry Lynd Dr. Carlo Marra Dr. Joel Singer

Regal B

1700 – 1900 Welcome Reception and Scientific Poster Exhibition Salon Lobby

Abstracts are available on the USB stick in the delegate kit, online at www.cadth.ca/symposium2015, and through the CADTH Symposium App.

PROGRAM AT A GLANCE

3 | Page

MONDAY, APRIL 13, 2015 Time Event Speakers Location 0730 – 1700 Registration Desk Open Main Level Lobby 0745 – 0845 Breakfast Salon Lobby

0845 – 0915 OFFICIAL OPENING Dr. Brian O’Rourke The Honourable

Dustin Duncan

Salon B/C/D

0915 – 1030 OPENING PLENARY SESSION We Know What the Evidence Says… Is Anybody Listening?

Dr. Tammy Clifford Gail Attara Dr. Édouard Hendriks Suzanne McGurn Dr. Jon Witt

Salon B/C/D

1030 – 1100 Refreshment Break Salon Lobby 1100 – 1230 Concurrent Session A1

In Search of Efficiency, Consistency, Fairness, and Impact in HTA: The Case for Clinical Pathway Management and Modelling

Dr. Stirling Bryan Dr. Graham Scotland Dr. Mohsen Sadatsafavi

Gallery A

Concurrent Session A2 Valuing Medical Technologies

Nicole Dekort Dr. Christina Farup Dr. Don Juzwishin Chantale Lessard Janey Shin Dr. Zayna Khayat Kevin Samra

Regal B

Concurrent Session A3 Public Policy in the Post-Interferon Era: Can We Afford to Cure Hepatitis C?

Dr. Murray Krahn Dr. William Wong Dr. Alnoor Ramji Kevin Wilson Susan Pierce

Gallery B

Concurrent Session A4 New Methods in HTA to Support Policy and Practice: Can We Better Understand How Canadians Value Health?

Dr. Jeffrey Hoch Dr. Nick Bansback Dr. Carlo Marra Dr. Dean Regier Mike Paulden

Gallery C

Concurrent Session A5 The Role of Patients in Defining “Value” and Engaging in Drug Development From Bench to Bedside

Louise Binder Ken Bond Dr. Deborah Marshall Dr. Pauline McNulty Dr. Laura Faye

Salon E

Concurrent Session A6 Drug Class Reviews: Bridging Evidence, Values, and Health Policy

Dr. Paul Oh Dr. Muhammad

Mamdani Dr. Doug Coyle Dr. George Wells

Gallery D

PROGRAM AT A GLANCE

4 | Page

MONDAY, APRIL 13 (cont’d)

Time Event Speakers Location 1100 – 1230 Concurrent Session A7

The Canadian Top Ten Watch List of New and Emerging Health Technologies: Methods, Lessons Learned, and Impact

Rosmin Esmail Cédric Jehanno Andra Morrison John Soloninka Alison Drinkwater Alain Boisvert

Blair Nelson

1230 – 1330 Lunch Salon Lobby

1330 – 1500 Concurrent Session B1 Cancer Care

Dr. S. Michelle Driedger Dr. Allan Grill Dr. Yvonne Bombard Reka Pataky

Gallery A

Concurrent Session B2 Patient Engagement in Health Technology Assessment (HTA)

Sarah Berglas Dr. Marc Rhainds Susan Bazylewski Louise Frederick

Gallery B

Concurrent Session B3 Rapid Reviews

Shannon Kelly Dr. Lisa Hartling Dr. Andrea Tricco

Regal B

Concurrent Session B4 Rural and Remote

Dr. Brenna Bath Stacey Lovo Grona Dr. Janice Mann

Blair Nelson

Concurrent Session B5 Drug Reimbursement Decisions

Elena Lungu Farzad Ali Dr. François Dionne Prof. Christopher

McCabe

Gallery C

Concurrent Session B6 Evidence on the Front Lines

Brendalynn Ens Dr. Mollie Butler Sheila Tucker Dr. Paule Poulin

Salon E

Concurrent Session B7 New Initiatives at CADTH

Anthony Budden David Crosbie Dr. Mona Sabharwal Dr. Chander Sehgal

Gallery D

1500 – 1530 Refreshment Break Salon Lobby



PROGRAM AT A GLANCE

5 | Page

MONDAY, APRIL 13 (cont’d)

Time Event Speakers Location

1530 – 1700 Concurrent Session C1 Impact of HTA Therapeutic Reviews on Real-World Clinical Practice: Multiple Sclerosis as a Case Study

Kristen Chelak Dr. Alasdair Coles Dr. Karen Lee Colin Vicente

Gallery A

Concurrent Session C2 New Methods in HTA to Support Policy and Practice: How Can We Better Conduct and Present Economic Evaluations?

Dr. Nick Bansback Dr. Mohsen

Sadatsafavi Prof. Christopher

McCabe Dr. Stirling Bryan Dr. Bohdan Nosyk

Gallery B

Concurrent Session C3 The Evidence — Decision-Making Disconnect: Evidence is Often Not Enough

Shahira Bhimani Dr. Zayna Khayat Dr. Don Juzwishin John Soloninka

Regal B

Concurrent Session C4 HTA on the Front Lines: Using the Evidence in Clinical Practice

Maureen Klenk Dr. Janice Mann Dr. Paul Salomon

Salon E

Concurrent Session C5 Daring to Be Rare: Researchers, Regulators, HTA Organizations Striving to Meet the Needs of Patients With Rare Diseases

Dr. Thierry Lacaze Kirsten Harkins Dr. David Whiteman Dr. Neil Cashman Philip Schwab

Gallery C

Concurrent Session C6 Exploring Opportunities for Collaboration Across the Spectrum of Formulary Decision-Making: From Hospitals to Health Authorities to Public Drug Plans

Sirjana Pant Faith Louis Dr. William Semchuk Dr. Eric Lun Anne Hiltz Stephanie Smith

Gallery D

1830 – 2230 SOCIAL EVENT - 1910 Boomtown Dinner Separate ticket required.

Western Development Museum



PROGRAM AT A GLANCE

6 | Page

TUESDAY, APRIL 14, 2015


0700 – 1500 Registration Desk Open

0700 – 0815 Breakfast Salon Lobby

0715 – 0815 Breakfast Session 1 Quick and Snappy: A Decade of Rapid Response Evidence

Chris Kamel Gallery A

Breakfast Session 2 CADTH Microsoft Excel-Based Tools for Conducting Health Technology Assessments — An Overview

Chris Cameron Dr. Tammy Clifford Dr. Michelle Mujoomdar

Gallery B

Breakfast Session 3 How HTA Recommendations Inform Decision-Makers on Subsequent Entry Biologics (SEBs): Post-HTA and Back Again

Dr. Brian Feagan Cheryl Koehn Angela Rocchi Dr. Chander Sehgal Dr. Carlyn Volume-Smith Michele Evans

Gallery C

Breakfast Session 4 CADTH Update of the Guidelines for the Economic Evaluation of Health Technologies: Canada — Process and What’s Next

Karen Lee Dr. Stirling Bryan Dr. Doug Coyle Dr. Murray Krahn Dr. Carlo Marra Prof. Christopher McCabe

Gallery D

0830 – 0945 PLENARY SESSION 2 Evidence of Value or Value of Evidence

Dr. Jeffrey Hoch Vivian Coates Dr. Tony Fields Anne Lee Dr. Alric Rüther

Salon B/C/D


1015 – 1145 Concurrent Session D1 Pharmaceutical Policy Issues

Dr. William Wong Satyin Kaura Denise Budz Dr. Qaiser Fahim Kathy Gesy

Gallery A

Concurrent Session D2 Medical Devices: Innovation, Assessment, Procurement

Dr. Lois Macklin Diane Simone Warren Dr. Fiona Miller

Salon E

Concurrent Session D3 Patient-Reported Outcomes

Deborah Bulych Prof. Christopher McCabe Dr. David Whitehurst

Blair Nelson

PROGRAM AT A GLANCE

7 | Page

TUESDAY, APRIL 14, 2015 (cont’d)


1015 – 1145 Concurrent Session D4 Health Economics

Mike Paulden Lidia Engel Lisa Masucci

Gallery C

Concurrent Session D5 Network Meta-Analysis

Dr. Areti-Angeliki Veroniki Dr. Petros Pechlivanoglou Steve Kanters

Regal B

Concurrent Session D6 Supporting Policy and Practice

Maureen Klenk Leah Clement Dale Backlin Jacqueline Messer-Lepage Sheila Tucker

Gallery B

Concurrent Session D7 Patient and Public Engagement

Dr. Dean Regier Dr. Julia Abelson Dr. Michael Burgess

Gallery D

1145 – 1300 Awards Luncheon Plated lunch. Please arrive promptly.

Salon B/C/D

1300 – 1430 Concurrent Session E1 Integrating Evidence, Values, and Ethics From Policy to Practice: A Multi-criteria Reflection

Dr. Cheri Deal Dr. Mireille Goetghebeur Christa Harstall Dr. Janet Martin

Gallery A

Concurrent Session E2 Improving the Appraisal of Non-Drug Technologies: Revising the Ontario Decision Framework

Dr. Fiona Miller Dr. Murray Krahn Dr. Ann-Sylvia Brooker

Gallery B

Concurrent Session E3 A Canadian Value Set for the EQ-5D-5L: One Answer, More Questions

Dr. Feng Xie Dr. Jeff Johnson Dr. Stirling Bryan Dr. Nick Bansback

Regal B

Concurrent Session E4 Evolving Foundations: Impacts of Adaptive Clinical Trial Design on Market Authorization and Reimbursement

Dr. Stuart MacLeod Kristian Thorlund Dr. Newell McElwee Barbara Sabourin Dr. Anthony Fields

Gallery C

Concurrent Session E5 Cross-Canada Collaboration to Promote Evidence-Based Use of Anticoagulants

Dr. Sarah Jennings Lynette Kosar Dr. Bronwen Jones Isobel Fleming Dr. Cait O’Sullivan

Salon E

PROGRAM AT A GLANCE

8 | Page

TUESDAY, APRIL 14, 2015 (cont’d)


1300 – 1430 Concurrent Session E6 The Evolving Role of Real-World Evidence to Support Policy and Practice

Don Husereau Julia Brown Peter Fenwick Neil Corner

Gallery D


1500 – 1615 CLOSING PLENARY The Health Technologies of Tomorrow — Will We Be Ready?

Dr. Brian O’Rourke Dr. Jenny Basran Dr. Brendan Carr Dr. Thomas Luby Dr. Tofy Mussivand Sharon Lee Smith

Salon B/C/D

1615 – 1630 Official Closing Dr. Brian O’Rourke Salon B/C/D



SPECIAL EVENTS

9 | Page

WELCOME RECEPTION AND SCIENTIFIC POSTER EXHIBITION

Sunday, April 12 1700 – 1900 Salon Lobby

The Welcome Reception features scientific posters and the opportunity to meet and talk with the authors about their work. A cash bar and light snacks will be available.

SOCIAL EVENT: 1910 BOOMTOWN DINNER

Monday, April 13 1830 – 2230

Meet at front door of TCU Place for

bus pick-up.

Shuttle will leave at 6:15 p.m. sharp.

Join us at the Western Development Museum where you’ll be transported back to a time when the clip-clop of horses filled the air. You don’t just visit this museum – you live it.

Take a stroll down the main street of Boomtown Saskatchewan circa 1910, stopping for drinks and hors d’oeuvres or a chat with the blacksmith and other locals. Tuck into a dinner featuring hearty traditional dishes and unique prairie flavours served in the midst of Saskatchewan’s largest collection of vintage cars and trains. Tour the exhibits, including the Cancer Bomb and Winning the Prairie Gamble before the evening wraps up with some toe-tapping tunes with the band, Don Griffith and The Second Line.

CADTH RECOGNITION AWARDS LUNCHEON

Tuesday, April 14 1145 – 1300 Salon B/C/D

Join us in honouring the 2015 recipients of the CADTH Recognition Awards. Presentations will be made to winners of the Dr. Jill M. Sanders Award of Excellence in HTA and the Maurice McGregor Award. The winners of our poster competition will also receive their awards at this luncheon. As this is a plated lunch, please arrive promptly.

PLENARY SESSIONS

10 | Page

April 13, 2015 0845 – 0915

OFFICIAL OPENING

Dr. Brian O’Rourke, President and CEO of the Canadian Agency for Drugs and Technologies in Health, will welcome Symposium participants, describe some of the Symposium highlights and introduce The Honourable Dustin Duncan.

Mr. Duncan was first elected as MLA for the constituency of Weyburn-Big Muddy in a by-election in June 2006 at the age of 26. In Opposition, he served on the Crown and Central Agencies Committee and as Critic for Youth Opportunities and Immigration. Re-elected in the 2007 general election, Mr. Duncan served as Chair of the Standing Committee on Crown and Central Agencies prior to entering Cabinet. On May 29, 2009 Premier Brad Wall appointed Dustin Duncan to the Saskatchewan Cabinet as Minister of Tourism, Parks, Culture and Sport. Appointed two months before his 30th birthday, Mr. Duncan is the youngest cabinet minister in Saskatchewan history and one of the youngest in Canadian history. On June 29, 2010, Mr. Duncan was appointed as Minister of Environment, Minister Responsible for Saskatchewan Water Corporation and Minister Responsible for SaskEnergy Incorporated. Minister Duncan was re-elected by his constituents in 2011. On May 25, 2012, he was appointed as Minister of Health. In addition to his various legislative roles, Mr. Duncan has served as a member of the Saskatchewan Legislative Internship Program Advisory Committee and in 2007 was named a BILLD Fellow after completing the Bowhay Institute for Legislative Leadership Development program at the University of Wisconsin - Madison. Mr. Duncan is active in his community and is a past board member of the Family Place, a community funded, community driven resource center for families in Weyburn and the surrounding area. Mr. Duncan grew up in Halbrite and graduated from Weyburn Comprehensive High in 1997. Mr. Duncan went on to complete an undergraduate degree in Canadian History from the University of Regina, graduating in 2002. He also completed the Canadian Securities Course. Dustin and his wife Amanda, a musician, were born, raised and educated in the Weyburn area. They make their home on a farm east of Weyburn – the same land Dustin’s great-grandparents farmed nearly a century ago. On June 28th, 2014 Dustin and Amanda proudly welcomed Jack, their son and newest member of their family into the world.

PLENARY SESSIONS

11 | Page

PLENARY 1 April 13, 2015 0915 – 1030

We Know What the Evidence Says… Is Anybody Listening

Health technology assessment (HTA) is a powerful tool that supports improved patient outcomes and health system sustainability. Sometimes, however, decisions are inconsistent with the evidence provided by HTA organizations. When that happens, it is hard not to wonder if anybody is listening. A panel will provide different perspectives on the role evidence plays in their decision-making and talk about other factors they consider. Here are some of the questions the panel will discuss: Is evidence considered when procurement decisions are made? What can be done to encourage health care providers to use evidence from HTA? Can health care professionals play a role in moving out-of-date technologies out of the health system? What evidence do patients value most? What can be done to ensure that HTA informs every health technology decision? What can be done to ensure that everybody is listening?

Gail Attara is the Chief Executive Officer of the Gastrointestinal Society. Gail’s motto, “the patient comes first,” directs her resolve for patient-focused health care and commitment to increasing awareness about the seriousness of gastrointestinal illnesses. Ms. Attara is an active community volunteer in Canada serving on numerous Boards and overseas, where she has worked with orphans. She has been an invited speaker coast-to-coast on numerous occasions, to wide-ranging audiences, including doctors, patients, pharmacists, and health care decision-makers. Participating as a member of the Best Medicines Coalition since 2005, Ms. Attara is now serving in her fifth year as its Chair. She is also co-counder of Advocacy Boot Camp, focussing her goal to expand the network of knowledgeable patient advocates within the health care system.

Dr. Édouard Hendriks is Vice-President of Medical, Academic and Research Affairs for the Horizon Health Network in New Brunswick. His portfolio includes medical manpower, the organization of medical services, academic affairs, relations with medical schools and oversight of reseach activities within the organization. He is the former President and CEO of Regional Health Authority 4 in Edmundston, New Brunswick, and has held various clinical and senior administrative positions with the Canadian Armed Forces and health institutions in Quebec, Ontario, and New Brunswick. Dr. Hendriks obtained his Master of Health Administration from the University of Ottawa, and his medical degree from the Université Laval in Quebec. He has a certificate in family medicine and a special certificate in emergency medicine, both from the College of Family Physicians of Canada. He is also a Fellow of the College. Dr. Hendriks has been a surveyor for Accreditation Canada for over 20 years. He has been and is involved with numerous national and provincial committees such as the Advisory Council for the EXTRA Program of the Canadian Health Services Research Foundation, the National Collaborating Centre for Healthy Public Policy, and the Board of Directors of the Canadian Patient Safety Institute.

PLENARY SESSIONS

12 | Page

Suzanne McGurn is the Assistant Deputy Minister and Executive Officer (Interim) of Ontario Public Drug Programs. She is also the Assistant Deputy Minister in the Health Human Resources Strategy Division, Ministry of Health and Long-Term Care, and has been since 2011.McGurn has worked in health care environments for more than 25 years. She spent the first 15 years of her career in a variety of clinical, front-line, and service provision roles. This gave her the opportunity to see the difference health care providers make every day in touching the lives of patients and their families, often when they are at their most vulnerable. Despite her love of nursing, in 2000 McGurn accepted an offer from the Ontario government to explore public policy. Since then, she has held a number of positions over her 10-plus years with the Ministry. McGurn holds both a Bachelor of Science in Nursing and a Master of Public Administration from Queen’s University.

Dr. Jon Witt is a graduate of the University of Saskatchewan's College of Medicine, with subsequent residency training in emergency and family medicine, as well as a Master of Public Health. Clinically, he is an attending emergency physician in Saskatoon and a transport physician for STARS — the Shock Trauma Air Rescue Society. Dr. Witt has a strong interest in knowledge translation and systems of care, and is a member of the Saskatchewan Integrated Stroke Strategy steering committee.

MODERATOR: Dr. Tammy Clifford is the Vice-President, Strategic Initiatives, and Chief Scientist at CADTH. Her responsibilities include aligning the methods used in conducting CADTH's health technology assessments (HTAs) with best practices. She is also responsible for building capacity among producers and users of evidence-based assessments by providing education, training, and various brokering activities that facilitate the sharing of HTA work. Her portfolio also includes overseeing the Policy Forum, the Canadian Network for Environmental Scanning in Health (CNESH), the Health Technology Analysis Exchange, and horizon scanning. Dr. Clifford provides leadership to CADTH's scientific advice (early engagement) program, and to the agency's patient and citizen engagement activities. She has a keen interest in advancing evidence synthesis methods, and in promoting the value of transparency and collaboration. Dr. Clifford joined CADTH in 2005 as Director, Project Quality, and was appointed Vice-President of the Health Technology Assessment Directorate in 2008. She holds faculty appointments in Pediatrics, and in Epidemiology and Community Medicine, at the University of Ottawa. Dr. Clifford received her PhD in Epidemiology and Biostatistics from the University of Western Ontario, and both her BSc and MSc from McGill University. She is actively engaged with a number of national and international entities including the Canadian Institutes of Health Research and Health Technology Assessment international (HTAi), and serves as a reviewer for The Lancet, JAMA Pediatrics, PLOS ONE, Health Policy, and the International Journal of Technology Assessment in Health Care.

PLENARY SESSIONS

13 | Page

PLENARY 2 April 14, 2015 0830 – 0945

Evidence of Value or Value of Evidence

Regulatory assessments and clinical trials are intended to provide proof of concept — whether a technology works; whereas reimbursement assessments or health technology assessments (HTAs) are intended to provide proof of value — whether a technology should be valued more highly than the alternatives. There are, however, many ways to look at value: from a financial to ethical, legal, and societal impact to patient preferences, and ease of use. In this session, an international panel of HTA experts will discuss whether cost-effectiveness carries more weight than other evidence, whether affordability trumps cost-effectiveness, and whether HTA is meeting the needs of decision-makers. Are there ways to increase the value of evidence and reduce the uncertainty that seems to go hand-in-hand with decision-making? What can be done to improve the availability, quality, and use of evidence in health policy development and clinical decision-making?

Vivian Coates is ECRI Institute’s Vice-President for Information Services and Health Technology Assessment (HTA). Ms. Coates developed and leads ECRI Institute’s evidence-based medicine and HTA program and works to enhance the program’s contribution to the health care community. Ms. Coates oversees ECRI Institute’s Evidence-based Practice Center (EPC), and all related evidence-based programs, including the Health Technology Assessment Information Service for hospitals and health systems, health plans, and health policy-makers. She initiates and fosters relationships with the users of comparative effectiveness research and HTA to promote the use of evidence-based medicine in health care purchasing, delivery, coverage, and clinical practice guideline development.

Dr. Anthony Fields, Professor Emeritus, Department of Oncology, University of Alberta and member of the medical staff at Alberta Health Services, recently retired from his appointment as Vice-President of Cancer Care at Alberta Health Services and Professor of Oncology, University of Alberta. During his time with Alberta Health Services, he was responsible for Alberta’s tertiary and associate cancer centres, community oncology program and cancer research programs. He received his medical degree from the University of Alberta and then trained in internal medicince and medical oncology at Toronto’s St. Michael’s Hospital and the Princess Margaret Cancer Centre respectively. In his clinical practice at the Cross Cancer Institute in Edmonton, he has specialized in the treatment of patients with gastrointestinal cancers. Dr. Fields has been recognized for his work by several awards, including an honorary doctorate of Athabasca University, the Distinguished alumni Award of the University of Alberta, and the R.M. Taylor Medal and Award of the Canadian Cancer Society and the National Cancer Institute of Canada. In Alberta’s centennial year 2005, he was named one of Alberta’s 100 Physicians of the Century. In 2012, he was appointed a Member of the Order of Canada. He is chair of the pan-Canadian Oncology Drug Review Expert Review Committee (pERC).

PLENARY SESSIONS

14 | Page

Anne Lee is the Chief Pharmacist for the Scottish Medicines Consortium (SMC). SMC is part of Healthcare Improvement Scotland and carries out health technology assessment of all new medicines. Trained as a pharmacist, Ms. Lee has practised in hospital pharmacy, specializing in medicines management, working in Edinburgh, Newcastle, and Glasgow. She has research experience in medicines safety and has edited textbooks on adverse drug reactions and safe prescribing in pregnancy and breastfeeding. Ms. Lee began working for SMC in 2005, initially to set up its horizon scanning programme, which supports financial planning in NHS Scotland through the provision of early intelligence on new medicines in development.

Dr. Alric Rüther studied philosophy and human medicine in Munich, Budapest, and Alicante (Spain) before training in internal medicine and oncology at the Universities of Munich and Freiburg, and has received further training in medical informatics. He also participated in the establishment of the German Cochrane Centre at the Institute for Medical Informatics and Biometry, University of Freiburg. Since 1999 he has been with the German Institute for Medical Documentation and Information (DIMDI), Federal Ministry of Health, and has worked to establish and build the discipline of health technology assessment (HTA) in German health care. Mr. Rüther was founder and head of the German Agency for HTA (DAHTA) from 2001 to 2007. In 2008, Mr. Rüther took over the responsibility of the Department of Health Care Quality at the Institute for Quality and Efficiency in Health Care (IQWiG). At IQWiG, Mr. Rüther is also responsible for the institute’s international relationships. Mr. Rüther has been engaged in worldwide HTA development since 1999. He is a member of the German Society for Medical Informatics, Biometry and Statistics; chair of the HTA working group; and a member of the German Network for Evidence-Based Medicine, chair of the field of HTA. Mr. Rüther is an associate professor at the Universities of Bielefeld and Berlin, lecturing on HTA.

MODERATOR: Jeffrey Hoch received his PhD in health economics from the Johns Hopkins Bloomberg School of Public Health. He also holds a Masters in Economics from Johns Hopkins University, and a Bachelor of Arts in Quantitative Economics and Decision Sciences from the University of California at San Diego. An award winning teacher, Dr. Hoch has taught Health Economics and Economic Evaluation classes in Asia, Europe, North and South America. In 2007, Dr. Hoch was asked to develop and direct the Pharmacoeconomics Research Unit at Cancer Care Ontario. As Director, Dr. Hoch has pursued research that seeks to make health economics more useful to decision-makers. Dr. Hoch is also the co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC is a national research centre funded by the Canadian Cancer Society and dedicated to cancer research, capacity building and knowledge transfer related to health economics, services, policy and ethics. Dr. Hoch’s research interests include health services research related to cancer, mental health, and other health issues affecting poor and vulnerable populations.

PLENARY SESSIONS

15 | Page

PLENARY 3 April 14, 2015 1500 – 1615

The Health Technologies of Tomorrow — Will We Be Ready? Regulators, health policy-makers, clinicians, payers, and health technology assessment (HTA) bodies are challenged by the pace of innovation in pharmaceuticals, medical devices, and procedures, and there are no signs that things will slow down anytime soon. Globally, there are more than 5,000 medicines in development with the potential to benefit Canadian patients, including precision medicines, therapeutic vaccines, numerous drugs for rate diseases and cancers, and gene therapies. Medical manufacturing companies are using 3-D printing to prototype and test products for a range of medical applications. Personal technologies (such as apps that allow your smart phone to double as a heart rate monitor or contact lenses that also monitor your blood sugar levels) have the potential to generate unprecedented volumes of personal data. Can this data be harnessed to improve the quality of care for individual patients and on a population health basis? Many of these new technologies will be disruptive to current clinical practice and reimbursement frameworks. Are we ready to manage the regulatory and reimbursement issues associated with these new technologies — and, if not, what do we have to do to get ready?

Dr. Jenny Basran is an Internist Geriatrician with a clinical practice that helps older patients and their families who are struggling with the challenges of cognitive and physical decline. In addition, Dr. Basran provides Internal Medicine services to the Acute Care Medicine service at Royal University Hospital. She has been the Head of the Division of Geriatric Medicine at the University of Saskatchewan since 2004. In this role, she has worked with the health region to restructure clinical services to meet the growing demand of an aging population. Through this process and her clinical experience, Dr. Basran has gained insight into both the gaps in the current system and how to effect change in a complex health system. She has led and participated in several regional, provincial, and national initiatives to improve health care for seniors. Dr. Basran has recently been named one of the physician co-leads for Saskatchewan Health's newest initiative, Emergency Department Waits and Patient Flow, a project aimed at decreasing wait times in emergency departments. Dr. Basran is a researcher with a tenured Associate Professor position at the University of Saskatchewan. She has received multiple national research grants from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada. Her research is in the area of technology and older adults. She has worked with engineers on the development of a falls detection system, as well as with computer scientists on an electronic health record for the hospitals and on technology to allow older adults to age in their homes safely. Dr. Basran is currently evaluating the feasibility of using technology products with older adults. She is examining the hypothesis that technology will increase the quality of life for older adults and their caregivers, while at the same time increasing quality and efficiencies in the health care system. She has a particular interest in improving the quality and accessibility of health care in rural areas.

PLENARY SESSIONS

16 | Page

Dr. Brendan Carr is the President and Chief Executive Officer of Vancouver Island Health Authority. He has held this position since August 6, 2013. Dr. Carr joined Island Health in March 2012 as the Executive Vice-President and Chief Medical Officer. Before joining the health authority, he served as Vice-President of Medicine with the Capital District Health Authority in Halifax and as an Assistant Professor at Dalhousie University. Dr. Carr holds Doctor of Medicine and Master of Business Administration degrees. He is a Canadian Certified Physician Executive and a Certified Health Executive and has completed a research fellowship with the Canadian Health Services Research Foundation. He is a skilled emergency department physician and continues to take an occasional shift in Emergency. Active in education and health services research, Dr. Carr is an advocate for innovation and transformation in health care.

Dr. Thomas Luby is Senior Director of New Ventures at Johnson & Johnson Innovation, Boston. He focuses primarily on cardiovascular and metabolic, infectious diseases and vaccines, and neurobiology. Prior to joining the Johnson & Johnson Family of Companies, Tom was the Sr. Director of Research Ventures at Shire Human Genetic Therapies. In this position, Tom played a central role in the evaluation, diligence, and deal processes across a number of successful early-stage investments in the rare disease space. He was member of the Board of Directors at Armagen Technologies, led the collaboration with Nimbus Discovery, and was instrumental in establishing and leading the alliance that Shire put in place with Atlas Venture. Prior to this, Tom held a variety of research and development roles in both start-up and mid-sized biotech. He has worked on multiple discovery through phase 2 programs in infectious disease, oncology, immunotherapy, and monogenetic disorders. His experience includes pre-clinical development, early-stage portfolio oversight, licensing, due diligence, company formation, alliance management, and key opinion leader outreach. Tom received his BS in Biology from State University of New York, his PhD in Immunology from Tufts University, and was a post-doctoral fellow in yeast genetics at Harvard School of Public Health.

Dr. Tofy Mussivand is Chair and Director of the Cardiovascular Devices Research Program at the University of Ottawa Heart Institute. He is also Chair of the Medical Devices program, Professor of Surgery in the Faculty of Medicine, and Professor of Engineering in the School of Information Technology and Engineering at the University of Ottawa. He has been actively involved in the medical devices field for more than 25 years in Canada and internationally. Mussivand received his undergraduate education and training in engineering and management. Following many successful years in senior positions in government, Crown corporations, and the private sector, he received his doctorate in Medical Engineering and Medical Sciences at the University of Akron and Northeastern Ohio Universities College of Medicine. Thereafter, he joined the internationally acclaimed Cleveland Clinic Hospital and Research Foundation, where he gained invaluable knowledge and experience in the development of medical devices, artificial hearts, and cardiac care. In 1989, he was invited to return to Canada to continue his pioneering work in the field of medical devices. Mussivand has achieved national and global recognition. His breakthroughs have led to Canada’s prominence in the fields of medical devices, artificial hearts, remote power transfer, and in situ sterilization. He has 15 patents to his name and another eight pending. Combining his scientific, management, and business expertise, Mussivand has chaired and served as a member on several

PLENARY SESSIONS

17 | Page

boards, and he has been a Chief Executive Officer of several successful corporations. His leadership has been responsible for creating more than 1,000 person-years in the Canadian workforce and has been the catalyst for an influx of more than $200 million, primarily from outside Canada, during the past 10 years. Mussivand is a Fellow of the International Academy of Cardiovascular Sciences and a Member of the European Academy of Sciences. In 2001, he won the Natural Sciences and Engineering Research Council of Canada University-Industry Synergy Award. He is a Fellow of the Royal Society of Canada (the highest scholarly honour in Canada) and has served the last three Canadian prime ministers as a member of the Prime Minister's Advisory Council on Science and Technology. Mussivand has published more than 250 papers, books, and technical articles, and he has supervised and taught more than 300 students, residents, and post-doctoral fellows.

Sharon Lee Smith has been Associate Deputy Minister (ADM), Policy and Transformation with the Ontario Ministry of Health and Long-Term Care since February 2015. An executive with more than 20 years of public service experience, Ms. Smith served most recently as ADM, Ministry of Health, Government of Saskatchewan. In this role, she was responsible for key areas, including public health, mental health and addictions, seniors’ and long-term care, laboratory services, and primary health care. Prior to joining the Ministry of Health in Saskatchewan, Ms. Smith was ADM for the Saskatchewan Region of Western Economic Diversification Canada. In 2013, as ADM, she received the Lieutenant Governor’s Gold Medal for Excellence in Public Administration. Her international work experience has included representing Canada in United Nations climate change negotiations in her role as Director General, International Affairs Branch, Environment Canada. She was also responsible for leading multilateral engagement and negotiations with international institutions, including the Organisation for Economic Co-operation and Development in Paris, Rome, and Nairobi, and the United Nations Environment Programme and the Commission for Sustainable Development in New York City. Sharon Lee has held leadership positions at Health Canada, as Regional Director for Northern Health and Executive Director, Aboriginal Health Secretariat – First Nations and Inuit Health Branch.

MODERATOR: Dr. Brian O’Rourke is the President and Chief Executive Officer of CADTH. He joined CADTH in January of 2009 as Vice-President of the CADTH Common Drug Review, following a distinguished career as a Pharmacist and Health Services Operations Officer with the Canadian Forces. With more than 30 years of experience in health care, Dr. O’Rourke actively positions CADTH as the leading source of health technology information in Canada. Dr. O’Rourke holds a Bachelor of Science in Pharmacy from Dalhousie University and a Doctor of Pharmacy from the University of Toronto.

Join Canadian and International experts in the production and use of

evidence-based information on health technologies, in Ottawa, for three

days of education and networking.

MARK YOUR CALENDAR NOW: 2016 CADTH Symposium

April 10 – 12, 2016 SHAW Centre

Ottawa, Ontario

Watch cadth.ca/symposium2016 for more information or contact us by email at [email protected].

mailto:[email protected]

final program for the 2015 cadth symposium

Documents